系统(IUPAC)命名名称 | |
---|---|
(2S,3S)-3-[[5-fluoro-2-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl]amino]bicyclo[2.2.2]octane-2-carboxylic acid | |
临床数据 | |
商品名 | Pimodivir |
合法状态 | |
合法状态 |
|
识别信息 | |
CAS注册号 | 1629869-44-8 |
PubChem | CID 67286591 |
化学信息 | |
化学式 | C20H19F2N5O2 |
摩尔质量 | 399.4 |
| |
|
吡莫地韦(VX-787,JNJ-63623872)是一种抗病毒药,被开发用于治疗流感。它可作为流感病毒聚合酶碱性蛋白2的抑制剂,并在II期临床试验中显示出较好的疗效。[1][2][3]
参考文献
- ↑ Trevejo JM, Asmal M, Vingerhoets J, Polo R, Robertson S, Jiang Y, Kieffer TL, Leopold L. Pimodivir treatment in adult volunteers experimentally inoculated with live influenza virus: a Phase IIa, randomized, double-blind, placebo-controlled study. Antivir Ther. 2018;23(4):335-344. PubMeddoi:10.3851/IMP3212
- ↑ Finberg RW, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman RS, Kosoglou T, Vingerhoets J, Leopold L. Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial. J Infect Dis. 2019 Mar 15;219(7):1026-1034. PubMeddoi:10.1093/infdis/jiy547
- ↑ Beigel JH, Nam HH, Adams PL, Krafft A, Ince WL, El-Kamary SS, Sims AC. Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference. Antiviral Res. 2019 Jul;167:45-67. PubMed doi:10.1016/j.antiviral.2019.04.006